Survival Outcomes in Oral Tongue Cancer: A Mono-Institutional Experience Focusing on Age.
T-N tract
age
head neck cancer
overall survival
prognosis
tongue cancer
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
12
10
2020
accepted:
11
01
2021
entrez:
29
4
2021
pubmed:
30
4
2021
medline:
30
4
2021
Statut:
epublish
Résumé
The prognostic role of age among patients affected by Oral Tongue Squamous Cell Carcinoma (OTSCC) is a topic of debate. Recent cohort studies have found that patients diagnosed at 40 years of age or younger have a better prognosis. The aim of this cohort study was to clarify whether age is an independent prognostic factor and discuss heterogeneity of outcomes by stage and treatments in different age groups. We performed a study on 577 consecutive patients affected by primary tongue cancer and treated with surgery and adjuvant therapy according to stage, at European Institute of Oncology, IRCCS. Patients with age at diagnosis below 40 years totaled 109 (19%). Overall survival (OS), disease-free survival (DFS), tongue specific free survival (TSFS) and cause-specific survival (CSS) were compared by age groups. Multivariate Cox proportional hazards models were used to assess the independent role of age. The median follow-up time was 5.01 years (range 0-18.68) years with follow-up recorded up to February 2020. After adjustment for all the significant confounding and prognostic factors, age remained independently associated with OS and DSF (respectively, p = 0.002 and p = 0.02). In CSS and TSFS curves, the role of age seems less evident (respectively, p = 0.14 and p = 0.0.37). In the advanced stage sub-group (stages III-IV), age was significantly associated with OS and CSS with almost double increased risk of dying (OS) and dying from tongue cancer (CSS) in elderly compared to younger groups (OS: HR = 2.16 95%, CI: 1.33-3.51, p= 0.001; CSS: HR = 1.76 95%, CI: 1.03-3.01, p = 0.02, respectively). In our study, young patients were more likely to be treated with intensified therapies (glossectomies types III-V and adjuvant radio-chemotherapy). Age was found as a prognostic factor, independently of other significant factors and treatment. Also the T-N tract involved by disease and neutrophil-to-lymphocyte ratio ≥3 were independent prognostic factors. Young age at diagnosis is associated with a better overall survival. Fewer younger people than older people died from tongue cancer in advanced stages.
Identifiants
pubmed: 33912446
doi: 10.3389/fonc.2021.616653
pmc: PMC8075362
doi:
Types de publication
Journal Article
Langues
eng
Pagination
616653Informations de copyright
Copyright © 2021 Ansarin, De Berardinis, Corso, Giugliano, Bruschini, De Benedetto, Zorzi, Maffini, Sovardi, Pigni, Scaglione, Alterio, Cossu Rocca, Chiocca, Gandini and Tagliabue.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
BMC Cancer. 2011 Oct 11;11:438
pubmed: 21989154
Aust Dent J. 2003 Mar;48(1):50-4
pubmed: 14640158
Head Neck. 1998 Aug;20(5):363-8
pubmed: 9663661
Cancer Sci. 2012 Feb;103(2):161-8
pubmed: 22070675
Med Oral Patol Oral Cir Bucal. 2020 Jul 1;25(4):e523-e531
pubmed: 32520923
Appl Immunohistochem Mol Morphol. 2012 May;20(3):291-7
pubmed: 22505011
J Clin Oncol. 1998 Feb;16(2):745-53
pubmed: 9469366
J Laryngol Otol. 1990 Jul;104(7):544-8
pubmed: 2384710
Acta Otorhinolaryngol Ital. 2018 Jun;38(3):175-180
pubmed: 29984792
Anticancer Res. 1998 Nov-Dec;18(6B):4779-86
pubmed: 9891557
Head Neck. 2019 Aug;41(8):2756-2767
pubmed: 30942940
Head Neck. 2000 May;22(3):297-302
pubmed: 10748455
J Clin Oncol. 2007 May 20;25(15):2127-32
pubmed: 17513820
Surg Oncol. 2018 Sep;27(3):503-507
pubmed: 30217309
Head Neck. 2015 Apr;37(4):518-23
pubmed: 24532246
Int J Environ Res Public Health. 2020 Jun 04;17(11):
pubmed: 32512723
Laryngoscope. 1999 Feb;109(2 Pt 1):249-58
pubmed: 10890775
Head Neck. 2017 Feb;39(2):297-304
pubmed: 27696557
Int J Cancer. 2002 Sep 1;101(1):95-9
pubmed: 12209594
Otolaryngol Head Neck Surg. 2000 Jan;122(1):44-51
pubmed: 10629481
Oral Oncol. 2018 Sep;84:7-11
pubmed: 30115478
Head Neck. 2019 Mar;41(3):821-827
pubmed: 30600861
J Clin Lab Anal. 2015 Nov;29(6):437-43
pubmed: 25277347
J Oral Maxillofac Pathol. 2019 Sep-Dec;23(3):450-457
pubmed: 31942130
J Oral Maxillofac Surg. 2017 Jul;75(7):1555-1566
pubmed: 28061358
Oral Dis. 2019 Apr;25(3):730-741
pubmed: 30548550
Head Neck. 2006 Apr;28(4):330-8
pubmed: 16470878
Eur Arch Otorhinolaryngol. 2016 Nov;273(11):3987-3992
pubmed: 27149875
Cancer. 1985 Jan 15;55(2):441-4
pubmed: 3965099
Oral Oncol. 2006 Aug;42(7):718-25
pubmed: 16529977
Am J Surg. 1975 Oct;130(4):475-8
pubmed: 1166939
Oral Oncol. 2007 Oct;43(9):894-7
pubmed: 17307026
Laryngoscope. 2019 Sep;129(9):2076-2081
pubmed: 30575045
Laryngoscope. 2000 Oct;110(10 Pt 1):1623-6
pubmed: 11037814
J Oral Pathol Med. 2018 Jul;47(6):541-546
pubmed: 28922483
Front Oncol. 2019 Apr 30;9:339
pubmed: 31114760
J Pathol Transl Med. 2019 Nov;53(6):369-377
pubmed: 31602967
N Engl J Med. 1986 Sep 4;315(10):647
pubmed: 3736606
Head Neck. 2012 Sep;34(9):1255-62
pubmed: 22009800
Oncol Lett. 2014 Jun;7(6):2099-2102
pubmed: 24932296
J Laryngol Otol. 1986 Nov;100(11):1295-8
pubmed: 3794534
Head Neck. 2019 Sep;41(9):2960-2968
pubmed: 30985036
Head Neck. 1994 Mar-Apr;16(2):107-11
pubmed: 8021128
Oral Oncol. 2013 Jun;49(6):525-33
pubmed: 23490885
Acta Otorhinolaryngol Ital. 2009 Oct;29(5):259-64
pubmed: 20162027
Ai Zheng. 2008 Dec;27(12):1315-20
pubmed: 19080001
Oral Oncol. 2018 Dec;87:43-48
pubmed: 30527242
ANZ J Surg. 2003 Nov;73(11):899-904
pubmed: 14616566
Braz Oral Res. 2019 Nov 25;33:e103
pubmed: 31778473
Oral Oncol. 2009 Aug;45(8):e57-61
pubmed: 19362043
J Clin Oncol. 2011 Apr 10;29(11):1488-94
pubmed: 21383286
Onco Targets Ther. 2017 Aug 04;10:3917-3924
pubmed: 28831266
N Engl J Med. 2004 May 6;350(19):1937-44
pubmed: 15128893
JAMA Otolaryngol Head Neck Surg. 2016 Sep 1;142(9):857-65
pubmed: 27442962
Head Neck. 2010 Apr;32(4):499-503
pubmed: 19691028
Oral Oncol. 2017 Apr;67:146-152
pubmed: 28351569
J Clin Oncol. 2015 Oct 10;33(29):3269-76
pubmed: 26351335
BMC Cancer. 2020 Jun 17;20(1):568
pubmed: 32552873
ISRN Otolaryngol. 2014 Mar 10;2014:529395
pubmed: 24734200
Cancer. 2007 Oct 1;110(7):1429-35
pubmed: 17724670
Clin Cancer Res. 2014 Jul 15;20(14):3842-8
pubmed: 24874835
Oral Oncol. 2020 Nov;110:104875
pubmed: 32622292
Eur J Cancer. 2017 Sep;82:115-127
pubmed: 28654785
Oral Oncol. 2011 Mar;47(3):174-9
pubmed: 21257337
Maxillofac Plast Reconstr Surg. 2017 Dec 25;39(1):41
pubmed: 29302590
Histopathology. 2011 Jun;58(7):1127-35
pubmed: 21707713
Curr Oncol Rep. 2011 Apr;13(2):132-7
pubmed: 21234721
Arch Otolaryngol Head Neck Surg. 1996 Dec;122(12):1313-9
pubmed: 8956742
Head Neck. 2019 Jan;41(1):110-115
pubmed: 30536781
Cancer Manag Res. 2019 Aug 09;11:7597-7603
pubmed: 31496814
Indian J Med Paediatr Oncol. 2017 Jan-Mar;38(1):44-50
pubmed: 28469336
N Engl J Med. 2015 Aug 6;373(6):521-9
pubmed: 26027881
Br J Oral Maxillofac Surg. 2019 Dec;57(10):1092-1097
pubmed: 31677799
J Clin Oncol. 2013 Feb 20;31(6):744-51
pubmed: 23129742
N Engl J Med. 2004 May 6;350(19):1945-52
pubmed: 15128894
J Natl Cancer Inst. 1990 Nov 21;82(22):1746-52
pubmed: 2231769